Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Jefferies GILEAD SCIENCES Continued Good News on Improving Story (Filgotinib) July 1, 2019 Key TakeawayGILD announced incrementally positive news that supports our view that things are getting relatively better and the story is turning around. Based on a pre-NDA meeting and a discussion with the FDA around the recent positive Phase III data and the ongoing Phase II male toxicity study (MANTA), GILD announced that the FDA agreed there is a path forward to file an NDA for filgotinib in 2019. This is an incremental positive surprise as the Street has been uncertain about whether a filing in 2019 was even possible. When filgotinib's pivotal program started, the agency said GILD was required to complete the male toxicity study, which had been enrolling very slowly and therefore suggested an NDA filing later in 2020. Today's announcement makes a filing more likely to occur later this year, so GILD is not that far behind ABBV which filed around 6 months ago. An outstanding question is whether GILD has a priority review voucher handy and thus can keep the timing tight, since ABBV used a priority voucher for upadacitinib to expedite the regulatory decision to Q3:19.To be balanced and fair, we acknowledge from GILD's press release that there is a "path forward" to filing in 2019. It appears to us that the conversation would be likely conducting an interim pooled analysis in Q3 so that they could file upon that event. Other outstanding questions are of course if the male toxicity study turned out to be positive or negative and whether that would impact GILD's ability to file. If positive, we would certainly argue everything would be very good and GILD would be very competitive if not best-in-class compared to ABBV. If data was negative and the drug did cause a reduction in sperm count, this scenario wouldn't appear to block GILD's ability to file. Rather, it would be an issue in the label, which isn't too commercially relevant in our opinion given that these indications comprise of mostly females.
Lama Daila schreef op 30 juni 2019 16:19 :
www.researchpool.com/provider/bryan-g... Bryan Garnier: GALAPAGOS | Buy | FV EUR140 | (MANTA) With or Without You
Gilead is heading into a pre-BLA meeting to discuss data from the FINCHes trials and the filing timelines for filgotinib. The outcome of this meeting should be communicated in the coming weeks.
De link naar de volledige nota stond in de recente nota die AvantiAvanti hier plaatste:medias.bryangarnier.com/equity/pdf/FO...
Na de nu bekende updates gelezen te hebben, vind ik de updates wel positief, maar vindt de aanpassing van de koersdoelen wat beperkt. Ik had wel wat meer verwacht. Dat GS houden zegt en het koersdoel niet opkrikt naar de huidige koers vind ik wat tegenstrijdig "to put it mildly", zeker nadat Galapagos ook op hun conferentie present is geweest. Wellicht willen veel banken de 2e kwartaal rapportages van Gilead afwachten en daarbij mogelijk nieuws over het al of niet inzetten van de priority review. Als ik mij niet vergis kunnen wij nog updates verwachten van een 3 tal banken waaronder Berenberg. Wellicht dat die wel wat aan hun koersdoel doet.
Citi 9 juli 2019 Verhoogt pt van 115 euro naar 140 euroRaising Price Target to €140 on Likely Filgotinib US Filing in 2019
jp morgan 165 euro doel gezien deal.
Kempen 15 juli 2019This is how you do it. Gilead and Galapagos entered a collaboration granting Gilead options for ex-EU rights for anything coming from Galapagos' pipeline for the next 10 years in exchange for $3.95b upfront, $1.1b equity investment plus multibillion future milestones. In all, the deal seems like a total win-win for both parties where Gilead finally gets the late-stage pipeline and exciting R&D engine, and Galapagos gains a strong and committed commercial partner, who will help build Galapagos' own infrastructure, and desired independence from takeover attempts and financial markets, while further expanding the R&D to discover novel targets. Just reflecting the upfront, equity investments and the nearterm milestones and royalties on the proprietary pipeline in our model, without a potential commercial advantage from having Gilead as a partner, our PT goes to €180 ($160 for ADR) from €135 ($120). Galapagos continues to feature on our favorites list.
Extract uit Morgan Stanley update 15 juli 2019Long-term Collaboration Provides Opportunity for Both Gilead and Galapagos Gilead and Galapagos announced a $5.1B, 10 year strategic partnership for exEU rights to Galapagos' pipeline. The deal provides Gilead with a proven target discovery engine and expanded late-stage pipeline. It enables Galapagos to grow its discovery engine and build an integrated biopharma co. Gilead and Galapagos announce a 10 year strategic pipeline transaction: Gilead will pay $3.95B upfront and buy $1.1B of Galapagos stock at a 20% premium to the 30 day weighted average price ( €140.59/share) for rights to Galapagos' pipeline outside of Europe for 10 years. The deal excludes MOR106. Specifically, Gilead has the right to opt-in to any program post-PhII for $150M upfront and 20-24% in royalties. Current clinical programs GLPG1690 and GLPG1972 are also included with the former carrying a $325M US approval milestone and the latter a $250M opt-in after PhIIb and up to $750M in milestones. All programs carry 50/50 cost-sharing post opt-in. The filgotinib deal has been restructured to include 50/50 global cost sharing and a 50/50 profit split with Galapagos in the EU5 (expanded from just Benelux region). Importantly, Gilead's equity investment in Galapagos will bring Gilead's ownership to ~22%. Gilead will receive two warrants to increase its ownership to 29.9%, subject to a shareholder vote. The first warrant, with a 1 year term, can increase Gilead's stake to 25% with a €140.59 strike price. The second warrant, with a 10 year term, can increase Gilead's stake to 29.9% and carries a 20% premium to Galapagos' stock price when exercised. The deal also includes a 10 year standstill. Impact to Gilead (EW, PT $83): The practical impact of this transaction is that it grows Gilead's mid-to-late stage pipeline in inflammatory diseases overnight, providing key potential catalysts in the early-to-mid-2020s. Importantly, it also significantly expands Gilead's discovery capabilities and delivers a potential steady stream of pipeline opportunities, an area that has been lacking at Gilead. Importantly, in our conversations with mgt. we believe the rationale for this deal was a portfolio approach to expanding the long-term pipeline at Gilead and does not rest on a single asset. However, just as important, mgt. indicated it will continue to look toward opportunities to rebuild Gilead's pipeline suggesting that this is not the only deal it will pursue. Overall we see the strategic rationale for the deal as solid and look forward to mgt.'s full strategic plan in the fall. Impact to Galapagos: We see three key impacts from this deal. First, Galapagos now has the capital to prosecute its broad pipeline, but maintains the independence of early clinical decisions so that it can continue to drive key programs into the clinic and through proof-of-concept quickly. Second, mgt. can now expand its target discovery engine from ~500 to ~1,000 scientists to drive higher through-put of novel targets which in turn can lead to an expanded clinical pipeline. Finally, the deal also accelerates mgt.'s goal of delivering an integrated biopharma organization which will have a strong European commercial presence. Together this expands Galapagos' clinical and commercial potential.Morgan Stanley is currently acting as a financial advisor to Galapagos N.V. (“Galapagos") in relation to its agreement to enter into a 10-year global collaboration with Gilead Sciences, Inc. that covers Galapagos’ current and future portfolio (the “Collaboration”), as announced on July 14, 2019. The proposed transaction is subject to required regulatory approvals and other customary closing conditions and certain elements of the Collaboration are subject to the approval of Galapagos’ shareholders. Galapagos has agreed to pay fees to Morgan Stanley for its services that are contingent upon the consummation of the proposed transaction.
avantiavanti schreef op 15 juli 2019 10:45 :
Kempen 15 juli 2019
This is how you do it. Gilead and Galapagos entered a collaboration granting Gilead options for ex-EU rights for anything coming from Galapagos' pipeline for the next 10 years in exchange for $3.95b upfront, $1.1b equity investment plus multibillion future milestones. In all, the deal seems like a total win-win for both parties where Gilead finally gets the late-stage pipeline and exciting R&D engine, and Galapagos gains a strong and committed commercial partner, who will help build Galapagos' own infrastructure, and desired independence from takeover attempts and financial markets, while further expanding the R&D to discover novel targets. Just reflecting the upfront, equity investments and the nearterm milestones and royalties on the proprietary pipeline in our model, without a potential commercial advantage from having Gilead as a partner, our PT goes to €180 ($160 for ADR) from €135 ($120). Galapagos continues to feature on our favorites list. Vreemd, PT voor ADR is lager. Je zou denken dat het andersom moet zijn, toch? $180 en €160.
C200 schreef op 15 juli 2019 10:51 :
[...]
Vreemd, PT voor ADR is lager. Je zou denken dat het andersom moet zijn, toch?
$180 en €160.
tijd voor een bezoekje aan de brillennwinkel, maar het kijkt inderdaad te kloppen.
C200 schreef op 15 juli 2019 10:51 :
[...]
Vreemd, PT voor ADR is lager. Je zou denken dat het andersom moet zijn, toch?
$180 en €160.
Ze houden er al rekening mee dat de euro flink in waarde daalt denk ik zo..............
KBC verhoging:Beursblik: KBC Securities verhoogt koersdoel Galapagos Redactie De Aandeelhouder - maandag, 15 juli 2019 Koopadvies behouden. (ABM FN) KBC Securities heeft maandag het koersdoel voor Galapagos maandag verhoogd van 128,00 naar 145,00 euro met een ongewijzigd koopadvies. Volgens analist Lenny Van Steenhuyse heeft Galapagos een "royale deal" met Gilead getekend. Deze overeenkomst geeft volgens de analist Galapagos nog eens tien jaar de tijd om met zijn Amerikaanse partner programma’s na te streven terwijl het de mogelijkheid biedt om commerciële expertise te ontwikkelen in Europa. Onder de uitgebreide samenwerking ontvangt Galapagos een vooruitbetaling van 3,95 miljard dollar en investeert Gilead voor 1,1 miljard dollar in aandelen. Galapagos gaat deze middelen inzetten om haar R&D-activiteiten uit te breiden en te versnellen. Naar aanleiding van het nieuws over de investering van Gilead in Galapagos en een aanzienlijke kasinstroom tegen eind 2019, KBC Securities mikt op een instroom van 0,5 miljard euro, besloot de analist tot de koersdoelverhoging. Het aandeel Galapagos koerste maandag kort na opening 17,3 procent hoger op 150,55 euro.
Analyst Price Targets (Updated)RBC Sector Perform Price Target € 132 Citigroup Smith Barney Price Target € 140 JP Morgan Price Target € 165 Kempen Price Target € 180 KBC Price Target € 145 Jefferies & Co. Price Target € 130 Bryan Garnier & Co Price Target € 180
Wall Street Trader schreef op 15 juli 2019 12:02 :
Analyst Price Targets (Updated)
RBC Sector Perform Price Target
€ 132 Citigroup Smith Barney Price Target
€ 140 JP Morgan Price Target
€ 165 Kempen Price Target
€ 180 KBC Price Target
€ 145 Jefferies & Co. Price Target
€ 130 Bryan Garnier & Co Price Target
€ 180 Most of them are wrong.. but they'll catch up later.
Video: heel positief nieuws voor Galapagos FONDS KOERS VERSCHIL VERSCHIL % BEURS Galapagos 149,25 21,10 16,47 % Euronext Amsterdam (ABM FN-Dow Jones) Galapagos heeft een heel goede deal met Gilead gesloten. Dit zei analist Corne van Zeijl van Actiam voor de camera van ABM Financial News. Er zit volgens Van Zeijl echter ook "een negatieve kant" aan het verhaal voor beleggers. De overnamekansen voor Galapagos zijn "nihil" geworden. Al met al meent de analist echter dat het positief nieuws is voor Galapagos.www.youtube.com/watch?v=4XcWz5I_jqg Door: ABM Financial News.info@abmfn.nl Redactie: +31(0)20 26 28 999 © Copyright ABM Financial News B.V. All rights reserved.
SVB Leerink 15 juli 2019Galapagos, Long Recognized as Technical Powerhouse, Rewarded with Independence
Pl4 schreef op 15 juli 2019 12:17 :
[...]
Most of them are wrong.. but they'll catch up later.
Filgotinib’s deal term slightly changed.Fair value would be about € 180 But a lot of models / price targets are currently under review.
H.C.Wainwright&Co 15 juli 2019Gilead Opts for Decentralized R&D Model With a $5.1B Collaboration; Target to $205 From $150
Extract Nomura Instinet 15 juli 2019First Look: Galapagos NV (GLPG US, Buy) - GILD Deal: Best Outcome Short of M and A Christopher Marai, Ph.D. - ILLC On Sunday, July 14th, GLPG and GILD published a press release and hosted a conference call on a revised R&D collaboration with highly favorable terms for GLPG (PR here, presentation here, collaboration overview here). Briefly, GILD will pay GLPG $3.95bn upfront, and make a $1.1bn investment in the company (consisting of a subscription for new GLPG shares at 140.59 EUR per share, or ~$158.45). This investment increases GILD’s stake to 22% of issued and outstanding shares—however, the collaboration contains a 10-year standstill restricting GILD from trying to increase its stake beyond 29.9%. Overall, the deal is structured to give GILD access to GLPG’s pipeline and to yield some commercial control over filgotinib to GLPG in Europe. The deal also prevents GILD from taking over GLPG for the next 10 years, making this deal the best outcome for GLPG short of full acquisition, in our view. NOTE: our current target price is below the last closing as we evaluate our estimates; our rating remains Buy. Previous GILD/GLPG Deal: Filgotinib-Centric with GILD Taking Commercial Lead and 80:20 Cost Split. In 2016, GILD closed a licensing and collaboration agreement with GLPG for filgotinib. GILD has an exclusive, WW, royalty bearing license for filgotinib and was primarily responsible for development and regulatory approval. GILD was responsible for 80% of costs incurred (and GLPG responsible for 20%). GILD made an upfront license fee payment of $300mn and a $425mn equity investment in GLPG (at the time, representing 14.75% of GLPG’s outstanding share capital). GLPG was eligible to receive regulatory milestone-based payments of up to $755mn, sales-based milestone payments of up to $600mn, and tiered royalties on global net sales from 20-30% (with exception of certain co-promotion territories where profits would be split, which include the UK, Germany, France, Italy, Spain, the Netherlands, Belgium, and Luxembourg). Current Revised GILD/GLPG Deal: Greater GLPG Involvement in Commercializing Filgotinib in Europe, and 50-50 Cost Split; GILD Now Has Rights to GLPG1690 (IPF, Ph3) and GLPG1972 (OA, Ph2b). The new collaboration agreement retains GILDs WW rights and co-development with GLPG in UK, Germany, France, Italy, and Spain. However, GLPG now has exclusive rights in the Netherlands, Belgium, and Luxembourg. In exchange for this expanded commercial role, GLPG will now have to split the costs 50-50 with GILD instead of 20-80. Importantly, GILD now has rights to GLPG pipeline, including outright rights to GLPG1690 for idiopathic pulmonary fibrosis (IPF) and an option for rights on GLPG1972 for osteoarthritis (OA). If ‘1690 is approved, GILD will pay GLPG $325mn; if GILD exercises its option for ‘1972, GILD will pay $250mn after completion of the Ph2b in OA (and an additional $200mn if certain secondary endpoints are met). GLPG would be eligible for $550mn in regulatory and commercial milestones if GILD opts in on ‘1972. Conference Call Focus Was Around GLPG’s R&D Platform and Downplayed Recent Filgotinib Results as Driving Factor. We noted the conference call’s focus was on GILD’s interest in GLPG’s target and drug discovery platform. GILD emphasized their access to GLPG’s IP and programs in inflammation and fibrosis. GILD’s O’Day would not break down how GILD’s investment varied by assets and said that he believe their investment is holistic toward GLPG’s pipeline. In the Q&A, management from both companies downplayed the recent news on filgotinib US filing as an impetus for the deal—O’Day noted long-standing interest on expanding this collaboration (even prior to O’Day joining GILD), and the framework for the deal appears to have been largely set even prior to the recent filgotinib updates. ‘1690 and IPF: High Unmet Need Market with 200K Patients in US and EU; 2017 Sales of Poorly Tolerated Nintedanib and Pirfenidone Was $1.9bn. GILD now has rights to ‘1690, an autotaxin inhibitor to block the bioactive signaling molecule LPA. It is a first-in-class inhibitor of autotaxin. The Ph2b data from FLORA was published in the “The Lancet, Respiratory Medicine). No important safety or tolerability issues were identified, and FVC was stabilized at week 12. With respect to the current collaboration, GILD does not have access to any unblinded data from the ongoing Ph3 studies ISABELLA 1 and 2 but did have unblinded access to safety data. We believe this may be important, as we had previously been concerned about theoretical toxicity from blocking LPA in the CNS. GILD’s interest after seeing unblinded safety data bodes well for the drug, in our view. Recall, this is a high unmet disease population, where 50% of patients die within 2-5 years post-diagnosis. The SOC include pirfenidone and nintedanib, which only slow down decline in lung function and are poorly tolerated (25% discontinuation rate due to AEs). 2016 pricing for pirfenidone and nintedanib was ~$95K/year/patient.
Beursblik: InsingerGilissen verhoogt koersdoel Galapagos FONDS KOERS VERSCHIL VERSCHIL % BEURS Galapagos 150,60 22,45 17,52 % Euronext Amsterdam (ABM FN-Dow Jones) InsingerGilissen heeft het koersdoel van Galapagos verhoogd van 150,00 naar 200,00 euro met een ongewijzigd Aanbevolen advies. Dit bleek maandag uit een analistenrapport. Volgens analist Jos Versteeg heeft Galapagos een prachtige deal gesloten met Gilead Sciences waarbij het Belgisch-Nederlandse biotechbedrijf zijn zelfstandigheid behoudt. Versteeg wees voor de camera van ABM Financial News op twee belangrijke doelstellingen die Galapagos CEO Onno van de Stolpe heeft: het bedrijf zelfstandig houden en een onafhankelijke Europese farmaceut worden. Dat eerste is door de deal met Gilead gelukt gezien de wapenstilstand van 10 jaar. Volgens Versteeg hoeft Galapagos niet bang te zijn dat er een bod zal komen want Gilead kan zijn belang uitbreiden tot net onder 30 procent en "daarmee is het volstrekt zinloos voor een andere farmaceut om een bod te doen". Het tweede doel van de Galapagos topman, dat wil zeggen een onafhankelijke farmaceut worden, daar heeft hij "ook een grote stap mee gemaakt", vindt Versteeg, omdat Galapagos in de toekomst alle medicijnen in Europa zelf mag ontwikkelen en deels ook vermarkten. Het aandeel Galapagos noteerde maandagmiddag bijna 17 procent hoger op 149,75 euro. Door: ABM Financial News.info@abmfn.nl Redactie: +31(0)20 26 28 999 © Copyright ABM Financial News B.V. All rights reserved.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)